FRED HUTCHINSON CANCER CENTER
Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases
- Conditions
- First Posted Date
- 2006-04-25
- Last Posted Date
- 2010-05-07
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00317785
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2010-09-21
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT00313625
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer
- Conditions
- First Posted Date
- 2005-11-04
- Last Posted Date
- 2010-09-21
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT00248430
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma
- Conditions
- Contiguous Stage II Grade 2 Follicular LymphomaNodal Marginal Zone B-cell LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Marginal Zone LymphomaNoncontiguous Stage II Grade 2 Follicular LymphomaStage I Grade 1 Follicular LymphomaContiguous Stage II Grade 1 Follicular LymphomaCutaneous B-cell Non-Hodgkin LymphomaNoncontiguous Stage II Marginal Zone LymphomaSplenic Marginal Zone Lymphoma
- Interventions
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2017-05-22
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT00244855
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia
- Conditions
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2011-11-30
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00244829
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2015-08-21
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 130
- Registration Number
- NCT00217438
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸University of Rochester, Rochester, New York, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2010-09-21
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00217568
- Locations
- 🇺🇸
University of Washington School of Medicine, Seattle, Washington, United States
🇺🇸Pacific Gynecology Specialists, Seattle, Washington, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2010-09-21
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00217555
- Locations
- 🇺🇸
University of Washington School of Medicine, Seattle, Washington, United States
Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2010-09-15
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00217386
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Olympic Medical Center, Port Angeles, Washington, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2010-09-21
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00217529
- Locations
- 🇺🇸
Pacific Gynecology Specialists, Seattle, Washington, United States
🇺🇸University of Washington School of Medicine, Seattle, Washington, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States